European Global Times
SEE OTHER BRANDS

The most trusted news from Europe

European Global Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Global Times.

Press releases published on March 24, 2025

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying …

Shiba ZK to Launch ICO, Blending Meme Culture with Cutting-Edge Blockchain Technology

Shiba ZK to Launch ICO, Blending Meme Culture with Cutting-Edge Blockchain Technology

London, UK, March 24, 2025 (GLOBE NEWSWIRE) -- Shiba ZK, the new-generation meme coin, intends to list with an initial coin offering price at $0.001 per coin, increasing to $0.05 on the day the coin goes live, giving the early investors a lot of room for …

Icon Energy Corp. Announces Fleet Expansion with and Time Charter Contract for a 2020-Built, Scrubber-Fitted, Eco, Ultramax, Dry Bulk Carrier

Icon Energy Corp. Announces Fleet Expansion with and Time Charter Contract for a 2020-Built, Scrubber-Fitted, Eco, Ultramax, Dry Bulk Carrier

ATHENS, Greece, March 24, 2025 (GLOBE NEWSWIRE) -- Icon Energy Corp. (“Icon” or the “Company”) (Nasdaq: ICON), an international shipping company that provides worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing …

Aura Minerals Announces Renewal of Normal Course Issuer Bid and Concurrent Buyback Program for Brazilian Depositary Receipts

Aura Minerals Announces Renewal of Normal Course Issuer Bid and Concurrent Buyback Program for Brazilian Depositary Receipts

ROAD TOWN, British Virgin Islands, March 24, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (OTCQX: ORAAF) ("Aura Minerals" or the "Company") announces today that the Toronto Stock Exchange (the "TSX") has accepted the Company's notice …

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized …

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

        Boston (March 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced …

WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation

WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation

SAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced its Aquablation …

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS Clene planning to initiate the confirmatory Phase 3 RESTORE-ALS trial in subjects with ALS in mid-2025 Secured new $10.0 …

Juve Stabia Academy: Developing the Next Generation of Football Talent in Naples

Juve Stabia Academy: Developing the Next Generation of Football Talent in Naples

Brera Holdings (Maria Xing, Head of Investments and Daniel McClory, Executive Chairman) and investors pictured at Cercola Training Facility in Naples, where Juve Stabia Academy trains Dublin, Ireland, and Naples, Italy, March 24, 2025 (GLOBE NEWSWIRE) -- …

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients …

American Tungsten Corp. Applauds U.S. Presidential Executive Order to Increase Domestic Critical Mineral Production

American Tungsten Corp. Applauds U.S. Presidential Executive Order to Increase Domestic Critical Mineral Production

Vancouver, BC, March 24, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) applauds U.S. President Donald Trump’s Executive Order seeking to bolster the production of domestic …

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia ( …

Arsen Introduces AI-Powered Phishing Tests to Improve Social Engineering Resilience

Arsen Introduces AI-Powered Phishing Tests to Improve Social Engineering Resilience

PARIS, March 24, 2025 (GLOBE NEWSWIRE) -- Arsen, a leading cybersecurity company specializing in social engineering defense, today announced the full release of Conversational Phishing, a groundbreaking feature embedded in its phishing simulation platform. …

Rush Factory Oyj:n sijoittajakalenteri vuodelle 2025

Rush Factory Oyj:n sijoittajakalenteri vuodelle 2025

Rush Factory Oyj 24.3.2025 klo 13.00 Rush Factory Oyj:n sijoittajakalenteri vuodelle 2025 Tapahtuma   Hiljainen jakso alkaa 22.2.2025 Tilinpäätöstiedote julkaistaan 24.3.2025 Hiljainen jakso alkaa 30.3.2025 Q1 neljännesvuositiedote 29.4.2025 Tilinpäätös ja …

How CNH’s precision technology is helping farmers tackle water scarcity

How CNH’s precision technology is helping farmers tackle water scarcity

How CNH’s precision technology is helping farmers tackle water scarcity Basildon, March 24, 2025 Following World Water Day on March 22, CNH brands - Case IH and New Holland - continue to lead the way in breaking new ground in precision agriculture. As part …

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing –  – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to …

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from …

Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services

Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services

Represents first project to enter the ECO Synthesis™ Innovation Lab Core enzymes for ECO Synthesis™ technology have transitioned from research into development and scale-up as the first step in securing the raw materials supply chain REDWOOD CITY, Calif., …

Aller Media expands Agillic across the Nordics

Aller Media expands Agillic across the Nordics

Aller Media, the Nordic market leader within magazines and weeklies, rolls out Agillic to Finland, Norway, and Sweden to replicate success from Denmark. Founded in 1873, Aller Media is today the Nordic market leader within magazines and weeklies, creating …

XploraDEX Aims to Transform How Liquidity Works on The XRP Ledger – $XPL Token Presale Now Open!

XploraDEX Aims to Transform How Liquidity Works on The XRP Ledger – $XPL Token Presale Now Open!

ZURICH, March 24, 2025 (GLOBE NEWSWIRE) -- In a major leap for DeFi on the XRP Ledger, XploraDEX is introducing AI-powered liquidity automation, a game-changing solution designed to help traders, market makers, and liquidity providers unlock seamless trade …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service